CDKN2A gene inactivation in epithelial sporadic ovarian cancer

被引:0
作者
D Niederacher
H-Y Yan
H-X An
H G Bender
M W Beckmann
机构
[1] Heinrich-Heine-University,Department of Obstetrics and Gynaecology
[2] The Third Affiliated Hospital of Hebei Medical University,Department of Obstetrics and Gynaecology
来源
British Journal of Cancer | 1999年 / 80卷
关键词
gene; LOH; 9p21–22; RT-PCR; immunohistochemistry; ovarian cancer;
D O I
暂无
中图分类号
学科分类号
摘要
The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to uncontrolled cell growth. In order to determine the role of CDKN2A in the development of sporadic ovarian cancer, loss of heterozygosity at 9p21–22, homozygous deletion, mutation and methylation status of the CDKN2A gene as well as CDKN2A expression were examined in a panel of serous papillary ovarian cancer. The frequency of loss of heterozygosity (LOH) for one or more informative markers at 9p21–22 was 65% (15/23). The most common deleted region was located between interferon (IFN)-α and D9S171. Homozygous deletions and mutations of the CDKN2A gene were not found. There was no evidence of methylation in exon 1, but methylation in exon 2 of CDKN2A gene was found in 26% (6/23). Absence of CDKN2A gene expression was shown in 27% (6/22) at mRNA level and 21% (4/19) at protein level. These data suggest that the CDKN2A gene is involved in the tumorigenesis of ovarian cancer, but the mechanisms of CDKN2A gene inactivation in serous papillary ovarian cancer remains unclear.
引用
收藏
页码:1920 / 1926
页数:6
相关论文
共 220 条
  • [1] An HX(1995)ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues Int J Cancer 74 57-63
  • [2] Niederacher D(1996)Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction – a routine analytical approach Int J Gynecol Cancer 6 291-297
  • [3] Beckmann MW(1996)Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast Br J Cancer 73 1220-1226
  • [4] Göhring UJ(1996)Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients Oncology 53 441-447
  • [5] Scharl A(1994)Rates of p16 (MTS1) mutations in primary tumors with 9p loss Science 265 415-416
  • [6] Picard F(1995)LOH and mutation analysis of CDKN2 in primary human ovarian cancers Int J Cancer 63 222-225
  • [7] van Roeyen C(1994)Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in tumors Am J Hum Gene 55 143-149
  • [8] Schnürch HG(1993)Human epithelial ovarian cancer allelotype Cancer Res 53 2393-2398
  • [9] Bender HG(1996)Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation Cancer Res 56 2405-2410
  • [10] Beckmann MW(1998)Automated fluorescent analysis procedure for enzymatic mutation detection Clin Chem 44 731-739